India approves Covishield and Covaxin to counter Covid-19

India approves Covishield and Covaxin to counter Covid-19

In the latest development to fight against the Covid-19, the Drug Controller General of India (DCGI) has permitted the use of Covishield by Serum Institute of India and Covaxin by the home based Bharat Biotech. As of now, the governing authority has granted the vaccines for restricted use for an emergency.

Responding to the good news Prime Minister Narendra Modi tweeted,

Regional Director WHO South-East Asia Region, Poonam Khetrapal Singh said, “WHO welcomes the first emergency use authorization given to COVID-19 vaccine in the WHO South-East Asia Region. This decision taken today by India will help intensify and strengthen the fight against COVID-19 pandemic in the region. The use of the vaccine in prioritized populations, along with the continued implementation of other public health measures and community participation will be important in reducing the impact of COVID-19”.

Adar Poonawalla, CEO of Serum Institute of India tweeted,

Applauding the news, AIIMS Delhi director, Dr. Randeep Guleria said,” It’s a great day for our country and it’s a very good way to start the new year. Both vaccines are made in India. They are cost-effective & easy to administer. We should, in a very short period, start rolling out the vaccine. It’s important to understand that when we consider any vaccine, safety is paramount & therefore vaccine goes through various stages to make sure it’s safe, then only we come to human trials. All data is critically looked at by experts after which the vaccine is approved”. He also tweeted,

error: Content is protected !!